Tech Company Financing Transactions
X-tosis Funding Round
The Michael J. Fox Foundation for Parkinson's Research participated in a $2.7 million funding round for X-tosis. This venture round was announced on 6/23/2026.
Transaction Overview
Company Name
Announced On
6/23/2026
Transaction Type
Debt
Amount
$2,740,000
Round
Undisclosed
Proceeds Purpose
The funding will support advancement of XTS001, the lead candidate from the company's MitoXTS platform, a patented family of small-molecule inhibitors of voltage-dependent anion channel 1 (VDAC1) oligomerization, toward clinical development for the treatment of Parkinson's disease (PD).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3501 S Main Street 1
Gainesville, FL 32601
USA
Gainesville, FL 32601
USA
Phone
Website
Email Address
Overview
X-tosis, founded in 2024, is a precision-medicine biotechnology company developing first-in-class mitochondrial therapeutics for neurodegenerative diseases. Our approach builds on more than two decades of foundational research led by Professor Varda Shoshan-Barmatz, whose pioneering discoveries in mitochondrial dysfunction and apoptosis established VDAC1 as a critical regulator of neuronal survival. At X-tosis, we are advancing a new therapeutic strategy that targets the root drivers of neurodegeneration.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 6/23/2026: Concord SAS venture capital transaction
Next: 6/23/2026: Kyrok venture capital transaction
Share this article
About Database of VC Transactions
We record all VC transactions involving tech companies. VC investment data records reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








